Skip to main content
GENETIC TECHNOLOGIES LIMITED logo

GENETIC TECHNOLOGIES LIMITED — Investor Relations & Filings

Ticker · GTG ISIN · AU000000GTG7 LEI · 529900YYKY7FRC90M744 ASX Human health and social work activities
Open in API
Filings indexed 1,303 across all filing types
Latest filing 2023-02-06 Capital/Financing Update
Country AU Australia
Listing ASX GTG

About GENETIC TECHNOLOGIES LIMITED

https://gtglabs.com/

Genetic Technologies Limited is a molecular diagnostics company focused on the development and commercialization of predictive genetic risk assessment tools. The company specializes in the geneType platform, which integrates clinical risk factors with polygenic risk scores to provide comprehensive risk assessments for various chronic diseases. Its portfolio includes tests for breast cancer, colorectal cancer, prostate cancer, melanoma, type 2 diabetes, and coronary artery disease. By identifying individuals at high risk of developing these conditions, the company enables healthcare providers to implement personalized screening and preventative health strategies. Genetic Technologies Limited serves clinicians and patients globally, aiming to improve health outcomes through early detection and precision medicine.

Recent filings

Filing Released Lang Actions
Proposed issue of securities - GTG 5 pages 27.8KB
Capital/Financing Update Classification · 100% confidence The document is an announcement regarding a proposed issue of securities by Genetic Technologies Limited. It details the type of securities (warrants), the number to be issued, the proposed issue date, conditions including shareholder approval at the upcoming AGM, and other specifics related to the placement. There is no financial data or report content, but rather an update on capital raising activities and issuance of new securities. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2023-02-06 English
Application for quotation of securities - GTG 6 pages 27.6KB
Share Issue/Capital Change Classification · 100% confidence The document is an application for quotation of securities on the ASX, detailing the number and type of securities to be quoted, issue dates, and distribution schedules. It references a previous Appendix 3B announcement related to the issue of securities. The content focuses on the listing and quotation of new shares rather than financial results, management changes, or other report types. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes.
2023-02-06 English
Section 708A - Cleansing Notice 1 page 394.6KB
Capital/Financing Update Classification · 95% confidence The document is a cleansing notice under section 708A of the Corporations Act 2001 (Cth), related to a private placement of shares by Genetic Technologies Limited. It announces compliance with disclosure requirements and provides legal assurance about the placement shares issued without disclosure under Part 6D.2 of the Corporations Act. The document is short (1748 characters) and serves as a regulatory announcement about a capital raising event, not a full financial report or detailed financing update. Given the nature of the notice and the regulatory context, it fits best under Capital/Financing Update (CAP).
2023-02-06 English
Genetic Technologies Announces US$5M Registered Direct Offer 2 pages 158.2KB
Capital/Financing Update Classification · 95% confidence The document is an ASX market announcement titled 'Genetic Technologies Announces US$5 Million Registered Direct Offering.' It details the terms of a registered direct offering of American Depositary Shares, including the number of shares, price, use of proceeds, and registration statement references (Form F-3). The content focuses on fundraising and capital raising activities, with no financial statements or earnings data presented. The document is about a financing transaction and capital structure update, not a full financial report or earnings release. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is 6819 characters, sufficient to provide substantive details about the offering, supporting a high confidence classification.
2023-02-05 English
Proposed issue of securities - GTG 5 pages 28.4KB
Capital/Financing Update Classification · 100% confidence The document is an announcement from Genetic Technologies Limited regarding a proposed issue of securities, specifically a placement of ordinary fully paid shares. It details the number of securities to be issued, the issue price, the proposed issue date, and other related information such as fees to the lead manager and the purpose of the issue. There are no financial statements or detailed financial performance data included, and the document is focused on informing about the capital raising activity. This fits the definition of a Capital/Financing Update (CAP) filing, which covers updates on company fundraising and capital structure changes.
2023-02-05 English
Supplementary Announcement - Comprehensive Risk Test 3 pages 202.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX Market Announcement from Genetic Technologies Limited providing a supplementary update about the development and commercialization strategy of a new comprehensive risk test for breast and ovarian cancer. It discusses product details, market channels, patent information, clinical validation, and commercial pilot protocols. There are no financial statements, earnings data, or detailed financial analysis present. The document is a corporate announcement about product development and commercial progress rather than a financial report or regulatory filing. It is not a report publication announcement since it contains substantive information rather than just announcing a report release. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is not related to board changes, voting results, or legal proceedings. The content is primarily an update on product development and commercialization progress, which aligns best with a Regulatory Filing (RNS) as a general corporate announcement that does not fit other specific categories.
2023-02-05 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.